Now showing items 1-4 of 4
Marked neutropenia: Significant but rare in people with multiple sclerosis after alemtuzumab treatment.
BACKGROUND: Alemtuzumab is a CD52-specific monoclonal antibody that markedly depletes T and B lymphocytes and inhibits relapsing multiple sclerosis (MS). However, polymorphonuclear neutrophils also express CD52 and can be ...
Validation of an environmentally-friendly and affordable cardboard 9-hole peg test.
BACKGROUND: In multiple sclerosis (MS) upper limb neurological impairments, are an important driver of disability and handicap. The gold standard for assessing upper limb function is the 9-hole peg test (9HPT). One ...
How to start a blog.
Blogs that address issues of health and medical education run by clinical and research teams can have a profound impact on how patients access and navigate health information. Regularly updated websites are useful tools ...
Seroconversion following COVID-19 vaccination: can we optimize protective response in CD20-treated individuals?
Although there is an ever-increasing number of disease-modifying treatments for relapsing multiple sclerosis (MS), few appear to influence coronavirus disease 2019 (COVID-19) severity. There is concern about the use of ...